Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jul
18
Today In Oncology
COVID-19 Boosters Offer Protection for Patients With Cancer
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes
Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
Classifying Pancreatic Cysts Using AI Models
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo